News

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update. “We made significant progress over the course of the past year. We continue to be extremely active with the NPC patient and.
    03/18/2024

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,925,659 titled, “Methods for Treating Alzheimer's Disease,” with claims that cover the use of Trappsol® Cyclo™ for.
    03/14/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Cyclo Therapeutics, Inc. (CYTH) can hold. Click on Rating Page for detail.

The price of Cyclo Therapeutics, Inc. (CYTH) is 1.4047 and it was updated on 2024-05-16 09:01:00.

Currently Cyclo Therapeutics, Inc. (CYTH) is in undervalued.

News
    
News

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding Cyclo Therapeutics' U.S. Patent Application No. 17/289,137 titled, “Methods for Tre.
    Mon, Jan. 29, 2024

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therapeutics in an all-stoc.
    Wed, Dec. 27, 2023

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced a positive outcome from its recent Type C meeting with the U.S. Food and Drug Administration (FDA), held on Thursday, December 14, 2023 to discuss a full data review of the Company's Trappsol® Cyclo™ clinical deve.
    Mon, Dec. 18, 2023

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

  • NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH). Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own. KSF is seeking to determine whether this considera.
    Tue, Nov. 28, 2023

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced its abstract has been accepted for platform presentation at the 20th Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA. Details of the platform presentation are as follows: Title: TransportNPC™.
    Tue, Nov. 21, 2023
SEC Filings
SEC Filings

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/15/2024

Cyclo Therapeutics, Inc. (CYTH) - 10-K/A - Current report

  • SEC Filings
  • 04/29/2024

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/18/2024

Cyclo Therapeutics, Inc. (CYTH) - 8-K/A - Current report

  • SEC Filings
  • 03/04/2024

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 02/15/2024

Cyclo Therapeutics, Inc. (CYTH) - SC 13G/A

  • SEC Filings
  • 02/14/2024

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 01/22/2024

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/28/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/28/2023

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 12/28/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/26/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/18/2023

Cyclo Therapeutics, Inc. (CYTH) - 425

  • SEC Filings
  • 12/18/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 11/30/2023

Cyclo Therapeutics, Inc. (CYTH) - 425

  • SEC Filings
  • 11/30/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 11/30/2023

Cyclo Therapeutics, Inc. (CYTH) - EFFECT

  • SEC Filings
  • 11/22/2023

Cyclo Therapeutics, Inc. (CYTH) - 424B3

  • SEC Filings
  • 11/21/2023

Cyclo Therapeutics, Inc. (CYTH) - S-4/A

  • SEC Filings
  • 11/20/2023

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/14/2023

Cyclo Therapeutics, Inc. (CYTH) - S-4

  • SEC Filings
  • 11/07/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 10/31/2023

Cyclo Therapeutics, Inc. (CYTH) - SC 13D/A

  • SEC Filings
  • 10/24/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 10/23/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 10/20/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 09/27/2023

Cyclo Therapeutics, Inc. (CYTH) - 425

  • SEC Filings
  • 09/27/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 09/21/2023

Cyclo Therapeutics, Inc. (CYTH) - 425

  • SEC Filings
  • 09/21/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/22/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 08/21/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/21/2023

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 08/21/2023

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/14/2023

Cyclo Therapeutics, Inc. (CYTH) - SC 13D/A

  • SEC Filings
  • 08/07/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 08/03/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/02/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 07/31/2023

Cyclo Therapeutics, Inc. (CYTH) - DEF 14A

  • SEC Filings
  • 06/13/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 06/07/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 06/05/2023

Cyclo Therapeutics, Inc. (CYTH) - PRE 14A

  • SEC Filings
  • 06/02/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 05/19/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 05/18/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 05/18/2023

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/12/2023

Cyclo Therapeutics, Inc. (CYTH) - SC 13D

  • SEC Filings
  • 05/11/2023

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 05/08/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 05/04/2023

Cyclo Therapeutics, Inc. (CYTH) - 10-K/A - Current report

  • SEC Filings
  • 05/01/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 04/24/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 04/24/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 03/21/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 03/20/2023

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/17/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 03/10/2023

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 03/09/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 03/08/2023

Cyclo Therapeutics, Inc. (CYTH) - EFFECT

  • SEC Filings
  • 02/14/2023

Cyclo Therapeutics, Inc. (CYTH) - SC 13G/A

  • SEC Filings
  • 02/14/2023

Cyclo Therapeutics, Inc. (CYTH) - SC 13G

  • SEC Filings
  • 02/10/2023

Cyclo Therapeutics, Inc. (CYTH) - S-1/A

  • SEC Filings
  • 02/10/2023

Cyclo Therapeutics, Inc. (CYTH) - DEF 14A

  • SEC Filings
  • 01/31/2023

Cyclo Therapeutics, Inc. (CYTH) - S-1

  • SEC Filings
  • 01/27/2023

Cyclo Therapeutics, Inc. (CYTH) - PRE 14A

  • SEC Filings
  • 01/20/2023

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 01/03/2023

Cyclo Therapeutics, Inc. (CYTH) - 424B5

  • SEC Filings
  • 01/03/2023

Cyclo Therapeutics, Inc. (CYTH) - RW

  • SEC Filings
  • 11/23/2022

Cyclo Therapeutics, Inc. (CYTH) - S-1/A

  • SEC Filings
  • 11/21/2022

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/10/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 11/09/2022

Cyclo Therapeutics, Inc. (CYTH) - S-1

  • SEC Filings
  • 10/31/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/22/2022

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/15/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/04/2022

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 06/24/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 05/23/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 05/16/2022

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/12/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 05/04/2022

Cyclo Therapeutics, Inc. (CYTH) - DEF 14A

  • SEC Filings
  • 04/29/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 04/29/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 04/07/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 03/30/2022

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/11/2022

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 03/02/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 03/02/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 02/07/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 02/04/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 02/01/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 01/24/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 01/19/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 01/18/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 01/14/2022

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/15/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/10/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/06/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/02/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/01/2021

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 11/19/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 11/19/2021

Cyclo Therapeutics, Inc. (CYTH) - 424B5

  • SEC Filings
  • 11/18/2021

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 11/16/2021

Cyclo Therapeutics, Inc. (CYTH) - 424B5

  • SEC Filings
  • 11/16/2021

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/15/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 11/01/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/28/2021

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 09/28/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/15/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/03/2021

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 09/01/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/31/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/30/2021

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 08/16/2021

Cyclo Therapeutics, Inc. (CYTH) - 424B5

  • SEC Filings
  • 08/16/2021

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/16/2021

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 06/25/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 06/21/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 06/02/2021

Cyclo Therapeutics, Inc. (CYTH) - EFFECT

  • SEC Filings
  • 06/01/2021

Cyclo Therapeutics, Inc. (CYTH) - EFFECT

  • SEC Filings
  • 05/28/2021

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 05/26/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 05/24/2021

Cyclo Therapeutics, Inc. (CYTH) - S-3/A

  • SEC Filings
  • 05/21/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 05/21/2021

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/14/2021

Cyclo Therapeutics, Inc. (CYTH) - DEF 14A

  • SEC Filings
  • 04/29/2021

Cyclo Therapeutics, Inc. (CYTH) - PRE 14A

  • SEC Filings
  • 04/16/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 04/16/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 04/12/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 03/30/2021

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 03/24/2021

Cyclo Therapeutics, Inc. (CYTH) - S-3

  • SEC Filings
  • 03/19/2021

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/12/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 03/08/2021

Cyclo Therapeutics, Inc. (CYTH) - SC 13G/A

  • SEC Filings
  • 02/12/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 01/27/2021

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 01/25/2021

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/22/2020

Cyclo Therapeutics, Inc. (CYTH) - SC 13G

  • SEC Filings
  • 12/17/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/17/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/14/2020

Cyclo Therapeutics, Inc. (CYTH) - SC 13G/A

  • SEC Filings
  • 12/11/2020

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/11/2020

Cyclo Therapeutics, Inc. (CYTH) - 424B4

  • SEC Filings
  • 12/11/2020

Cyclo Therapeutics, Inc. (CYTH) - EFFECT

  • SEC Filings
  • 12/09/2020

Cyclo Therapeutics, Inc. (CYTH) - S-1MEF

  • SEC Filings
  • 12/09/2020

Cyclo Therapeutics, Inc. (CYTH) - EFFECT

  • SEC Filings
  • 12/08/2020

Cyclo Therapeutics, Inc. (CYTH) - CERT

  • SEC Filings
  • 12/08/2020

Cyclo Therapeutics, Inc. (CYTH) - 8-A12B

  • SEC Filings
  • 12/08/2020

Cyclo Therapeutics, Inc. (CYTH) - S-1/A

  • SEC Filings
  • 12/04/2020

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 12/04/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 11/25/2020

Cyclo Therapeutics, Inc. (CYTH) - S-1/A

  • SEC Filings
  • 11/17/2020

Cyclo Therapeutics, Inc. (CYTH) - S-1/A

  • SEC Filings
  • 11/16/2020

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/12/2020

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 11/10/2020

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 10/23/2020

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 10/06/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 10/01/2020

Cyclo Therapeutics, Inc. (CYTH) - S-1

  • SEC Filings
  • 09/29/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/28/2020

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 09/24/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/23/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/16/2020

Cyclo Therapeutics, Inc. (CYTH) - DEF 14A

  • SEC Filings
  • 09/15/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/11/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/08/2020

Cyclo Therapeutics, Inc. (CYTH) - PRE 14A

  • SEC Filings
  • 09/03/2020

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 09/03/2020

Cyclo Therapeutics, Inc. (CYTH) - SC 13D/A

  • SEC Filings
  • 09/02/2020

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 09/02/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/02/2020

Cyclo Therapeutics, Inc. (CYTH) - SC 13G/A

  • SEC Filings
  • 08/31/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/31/2020

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 08/31/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/28/2020

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/14/2020

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/15/2020

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 05/06/2020

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 04/29/2020

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 04/27/2020

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 04/27/2020

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/30/2020

Cyclo Therapeutics, Inc. (CYTH) - SC 13G/A

  • SEC Filings
  • 02/14/2020

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/14/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/30/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/19/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/18/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/13/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/12/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/11/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 09/09/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/29/2019

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 08/27/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/26/2019

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/13/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/02/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 07/31/2019

Cyclo Therapeutics, Inc. (CYTH) - DEF 14A

  • SEC Filings
  • 07/19/2019

Cyclo Therapeutics, Inc. (CYTH) - EFFECT

  • SEC Filings
  • 07/15/2019

Cyclo Therapeutics, Inc. (CYTH) - 424B3

  • SEC Filings
  • 07/15/2019

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 07/10/2019

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 07/10/2019

Cyclo Therapeutics, Inc. (CYTH) - PRE 14A

  • SEC Filings
  • 07/08/2019

Cyclo Therapeutics, Inc. (CYTH) - S-1

  • SEC Filings
  • 06/27/2019

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 06/21/2019

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 06/14/2019

Cyclo Therapeutics, Inc. (CYTH) - SC 13G

  • SEC Filings
  • 06/10/2019

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 06/07/2019

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 06/05/2019

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 06/04/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 06/03/2019

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/15/2019

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/15/2019

Cyclo Therapeutics, Inc. (CYTH) - SC 13G/A

  • SEC Filings
  • 02/19/2019

Cyclo Therapeutics, Inc. (CYTH) - SC 13G

  • SEC Filings
  • 02/15/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 01/02/2019

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/31/2018

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 12/28/2018

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/28/2018

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/27/2018

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 12/26/2018

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 11/13/2018

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/09/2018

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/14/2018

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 07/09/2018

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 07/09/2018

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 06/28/2018

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 05/24/2018

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/15/2018

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 04/25/2018

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 04/25/2018

Cyclo Therapeutics, Inc. (CYTH) - DEF 14A

  • SEC Filings
  • 04/16/2018

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 04/16/2018

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 04/10/2018

Cyclo Therapeutics, Inc. (CYTH) - PRE 14A

  • SEC Filings
  • 04/04/2018

Cyclo Therapeutics, Inc. (CYTH) - NT 10-K - Current report

  • SEC Filings
  • 04/02/2018

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 03/20/2018

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 02/06/2018

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 02/05/2018

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/01/2017

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/09/2017

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 11/08/2017

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 11/02/2017

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 10/27/2017

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 10/23/2017

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 10/20/2017

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 10/19/2017

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/11/2017

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 07/03/2017

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/12/2017

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 04/04/2017

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 04/03/2017

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/17/2017

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 03/03/2017

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 02/28/2017

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 02/27/2017

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/20/2016

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/10/2016

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/12/2016

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 07/26/2016

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 06/13/2016

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 06/10/2016

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 06/08/2016

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 06/08/2016

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/16/2016

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/30/2016

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 02/03/2016

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 01/27/2016

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/12/2015

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 11/09/2015

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 11/04/2015

Cyclo Therapeutics, Inc. (CYTH) - SC 13D/A

  • SEC Filings
  • 10/20/2015

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 10/16/2015

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 09/17/2015

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 08/31/2015

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/14/2015

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 07/23/2015

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 07/22/2015

Cyclo Therapeutics, Inc. (CYTH) - SC 13D/A

  • SEC Filings
  • 07/21/2015

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 07/14/2015

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 07/13/2015

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/15/2015

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/27/2015

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 02/17/2015

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 01/27/2015

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 01/22/2015

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/14/2014

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 10/03/2014

Cyclo Therapeutics, Inc. (CYTH) - SC 13D

  • SEC Filings
  • 08/14/2014

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/14/2014

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 08/05/2014

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 08/05/2014

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 07/31/2014

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 07/22/2014

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 07/09/2014

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 05/21/2014

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/09/2014

Cyclo Therapeutics, Inc. (CYTH) - SC 13G

  • SEC Filings
  • 04/29/2014

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 04/22/2014

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 04/21/2014

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 04/15/2014

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/04/2014

Cyclo Therapeutics, Inc. (CYTH) - D

  • SEC Filings
  • 03/03/2014

Cyclo Therapeutics, Inc. (CYTH) - SC 13D

  • SEC Filings
  • 02/28/2014

Cyclo Therapeutics, Inc. (CYTH) - SC 13D/A

  • SEC Filings
  • 02/24/2014

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 02/21/2014

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 02/21/2014

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 02/20/2014

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/13/2013

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 09/17/2013

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 09/03/2013

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 08/29/2013

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 08/21/2013

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/14/2013

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 08/08/2013

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 07/26/2013

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/08/2013

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/14/2013

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/13/2012

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/14/2012

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 07/13/2012

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/21/2012

Cyclo Therapeutics, Inc. (CYTH) - NT 10-Q - Quarterly Report

  • SEC Filings
  • 05/16/2012

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 05/16/2012

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/16/2012

Cyclo Therapeutics, Inc. (CYTH) - 10-Q/A - Quarterly Report

  • SEC Filings
  • 02/23/2012

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/18/2011

Cyclo Therapeutics, Inc. (CYTH) - NT 10-Q - Quarterly Report

  • SEC Filings
  • 11/14/2011

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/15/2011

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/13/2011

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 04/26/2011

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/30/2011

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 03/28/2011

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 02/28/2011

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 02/28/2011

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 02/24/2011

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 02/18/2011

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 02/11/2011

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 02/02/2011

Cyclo Therapeutics, Inc. (CYTH) - 10-Q/A - Quarterly Report

  • SEC Filings
  • 02/02/2011

Cyclo Therapeutics, Inc. (CYTH) - 10-K/A - Current report

  • SEC Filings
  • 02/02/2011

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 12/21/2010

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 12/13/2010

Cyclo Therapeutics, Inc. (CYTH) - NT 10-Q - Quarterly Report

  • SEC Filings
  • 11/16/2010

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/16/2010

Cyclo Therapeutics, Inc. (CYTH) - SC 13D

  • SEC Filings
  • 10/28/2010

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 10/28/2010

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 10/28/2010

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 09/17/2010

Cyclo Therapeutics, Inc. (CYTH) - 3

  • SEC Filings
  • 08/18/2010

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 08/17/2010

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/13/2010

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/14/2010

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/31/2010

Cyclo Therapeutics, Inc. (CYTH) - S-8

  • SEC Filings
  • 01/19/2010

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/13/2009

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/14/2009

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/15/2009

Cyclo Therapeutics, Inc. (CYTH) - 10-K - Current report

  • SEC Filings
  • 03/30/2009

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 01/13/2009

Cyclo Therapeutics, Inc. (CYTH) - 10KSB/A

  • SEC Filings
  • 01/08/2009

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 11/25/2008

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/14/2008

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 11/12/2008

Cyclo Therapeutics, Inc. (CYTH) - CORRESP

  • SEC Filings
  • 11/05/2008

Cyclo Therapeutics, Inc. (CYTH) - UPLOAD

  • SEC Filings
  • 09/03/2008

Cyclo Therapeutics, Inc. (CYTH) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/14/2008

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/15/2008

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 04/04/2008

Cyclo Therapeutics, Inc. (CYTH) - NT 10-K - Current report

  • SEC Filings
  • 04/01/2008

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/14/2007

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/14/2007

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/16/2007

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 04/02/2007

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/14/2006

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 11/02/2006

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 10/06/2006

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/14/2006

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/15/2006

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 03/31/2006

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/14/2005

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 09/22/2005

Cyclo Therapeutics, Inc. (CYTH) - S-8

  • SEC Filings
  • 09/06/2005

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 09/06/2005

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 08/16/2005

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/05/2005

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 07/20/2005

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/13/2005

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 03/29/2005

Cyclo Therapeutics, Inc. (CYTH) - S-1/A

  • SEC Filings
  • 02/17/2005

Cyclo Therapeutics, Inc. (CYTH) - SC 13D

  • SEC Filings
  • 02/09/2005

Cyclo Therapeutics, Inc. (CYTH) - SC 13D

  • SEC Filings
  • 02/04/2005

Cyclo Therapeutics, Inc. (CYTH) - S-1

  • SEC Filings
  • 01/06/2005

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/20/2004

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/05/2004

Cyclo Therapeutics, Inc. (CYTH) - DEF 14A

  • SEC Filings
  • 11/04/2004

Cyclo Therapeutics, Inc. (CYTH) - PRE 14A

  • SEC Filings
  • 10/19/2004

Cyclo Therapeutics, Inc. (CYTH) - DEF 14C

  • SEC Filings
  • 08/25/2004

Cyclo Therapeutics, Inc. (CYTH) - 10QSB/A

  • SEC Filings
  • 08/20/2004

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/20/2004

Cyclo Therapeutics, Inc. (CYTH) - 10KSB/A

  • SEC Filings
  • 08/20/2004

Cyclo Therapeutics, Inc. (CYTH) - NT 10-Q - Quarterly Report

  • SEC Filings
  • 08/13/2004

Cyclo Therapeutics, Inc. (CYTH) - PRER14C

  • SEC Filings
  • 07/30/2004

Cyclo Therapeutics, Inc. (CYTH) - PRER14C

  • SEC Filings
  • 07/19/2004

Cyclo Therapeutics, Inc. (CYTH) - S-8

  • SEC Filings
  • 06/08/2004

Cyclo Therapeutics, Inc. (CYTH) - PRE 14C

  • SEC Filings
  • 06/08/2004

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/13/2004

Cyclo Therapeutics, Inc. (CYTH) - SC 13G/A

  • SEC Filings
  • 04/26/2004

Cyclo Therapeutics, Inc. (CYTH) - S-8

  • SEC Filings
  • 04/15/2004

Cyclo Therapeutics, Inc. (CYTH) - 4/A

  • SEC Filings
  • 04/12/2004

Cyclo Therapeutics, Inc. (CYTH) - S-8 POS

  • SEC Filings
  • 04/01/2004

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 03/30/2004

Cyclo Therapeutics, Inc. (CYTH) - S-8

  • SEC Filings
  • 03/26/2004

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 03/05/2004

Cyclo Therapeutics, Inc. (CYTH) - 4

  • SEC Filings
  • 01/13/2004

Cyclo Therapeutics, Inc. (CYTH) - S-8

  • SEC Filings
  • 12/01/2003

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/14/2003

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/14/2003

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/15/2003

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 03/31/2003

Cyclo Therapeutics, Inc. (CYTH) - SC 13G

  • SEC Filings
  • 11/29/2002

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/14/2002

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/14/2002

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/16/2002

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 04/01/2002

Cyclo Therapeutics, Inc. (CYTH) - DEF 14A

  • SEC Filings
  • 03/08/2002

Cyclo Therapeutics, Inc. (CYTH) - PRE 14A

  • SEC Filings
  • 02/28/2002

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/14/2001

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/14/2001

Cyclo Therapeutics, Inc. (CYTH) - S-8

  • SEC Filings
  • 07/02/2001

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/15/2001

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 04/02/2001

Cyclo Therapeutics, Inc. (CYTH) - SC 13D

  • SEC Filings
  • 11/30/2000

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/14/2000

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/14/2000

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/15/2000

Cyclo Therapeutics, Inc. (CYTH) - SC 13G/A

  • SEC Filings
  • 04/06/2000

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 03/30/2000

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/15/1999

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/16/1999

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/14/1999

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 03/31/1999

Cyclo Therapeutics, Inc. (CYTH) - POS AM

  • SEC Filings
  • 03/05/1999

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/13/1998

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/14/1998

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/15/1998

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 03/31/1998

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/29/1997

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/21/1997

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/14/1997

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/15/1997

Cyclo Therapeutics, Inc. (CYTH) - S-8

  • SEC Filings
  • 05/12/1997

Cyclo Therapeutics, Inc. (CYTH) - 10KSB

  • SEC Filings
  • 04/01/1997

Cyclo Therapeutics, Inc. (CYTH) - DEF 14A

  • SEC Filings
  • 01/10/1997

Cyclo Therapeutics, Inc. (CYTH) - 424B3

  • SEC Filings
  • 01/10/1997

Cyclo Therapeutics, Inc. (CYTH) - ARS

  • SEC Filings
  • 01/09/1997

Cyclo Therapeutics, Inc. (CYTH) - 8-K/A - Current report

  • SEC Filings
  • 12/20/1996

Cyclo Therapeutics, Inc. (CYTH) - 8-K - Current report

  • SEC Filings
  • 12/12/1996

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 11/15/1996

Cyclo Therapeutics, Inc. (CYTH) - S-8

  • SEC Filings
  • 08/28/1996

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 08/14/1996

Cyclo Therapeutics, Inc. (CYTH) - S-8

  • SEC Filings
  • 07/22/1996

Cyclo Therapeutics, Inc. (CYTH) - SB-2/A

  • SEC Filings
  • 06/28/1996

Cyclo Therapeutics, Inc. (CYTH) - SB-2/A

  • SEC Filings
  • 06/11/1996

Cyclo Therapeutics, Inc. (CYTH) - 10QSB/A

  • SEC Filings
  • 06/11/1996

Cyclo Therapeutics, Inc. (CYTH) - 10QSB

  • SEC Filings
  • 05/15/1996
Press Releases
StockPrice Release

Cyclo therapeutics reports full year 2023 financial results and provides business update

  • 03/18/2024

Cyclo therapeutics announces issuance of u.s. patent covering the use of trappsol® cyclo™ for the treatment of alzheimer's disease

  • 03/14/2024

Cyclo therapeutics announces allowance of patent application for treatment of alzheimer's disease from the u.s. patent and trademark office

  • 01/29/2024

Cyclo therapeutics, inc. completes merger with applied molecular transport inc.

  • 12/27/2023

Cyclo therapeutics announces positive outcome from type c meeting with the u.s. fda discussing trappsol® cyclo™ clinical program for the treatment of niemann-pick disease type c1

  • 12/18/2023

Applied molecular investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of applied molecular transport inc. - amti

  • 11/28/2023

Cyclo therapeutics to present at the 20th annual worldsymposium™ 2024

  • 11/21/2023

Cyclo therapeutics reports third quarter 2023 financial results

  • 11/15/2023

Cyclo therapeutics announces early exercise of warrants by board members, management and a significant shareholder resulting in cash proceeds of $2.4 million

  • 10/23/2023

Cyclo therapeutics to present at 8th annual dawson james conference

  • 10/05/2023

Applied molecular investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of applied molecular transport inc. - amti

  • 09/27/2023

Cyth stock alert: halper sadeh llc is investigating whether the merger of cyclo therapeutics, inc. is fair to shareholders

  • 09/21/2023

Cyclo therapeutics, inc. and applied molecular transport inc. enter into a definitive merger agreement

  • 09/21/2023

Cyclo therapeutics reports second quarter 2023 financial results

  • 08/15/2023

Cyclo therapeutics announces closing of $5.0 million private placement with rafael holdings, inc.

  • 08/02/2023

Cyclo therapeutics announces publication of positive data from phase 2 clinical study of trappsol® cyclo™ for the treatment of niemann-pick disease type c1

  • 06/29/2023

Cyclo therapeutics announces allowance of patent from european patent office for trappsol® cyclo™ for alzheimer's disease

  • 06/12/2023

Cyclo therapeutics provides business update and reports first quarter 2023 financial results

  • 05/15/2023

Cyclo therapeutics announces closing of $1.3 million private placement priced at-the-market under nasdaq rules

  • 04/21/2023

Cyclo therapeutics provides business update and reports full year 2022 financial results

  • 03/20/2023

Cyclo therapeutics provides clinical program update and highlights recent achievements

  • 01/11/2023

Cyclo therapeutics to present at the virtual investor 2023 companies to watch event

  • 01/10/2023

Cyclo therapeutics announces first patient dosed in phase 2b study of trappsol® cyclo™ for the treatment of early alzheimer's disease

  • 01/09/2023

Cyclo therapeutics announces closing of $4.2 million registered direct offering priced at-the-market under nasdaq rules

  • 01/04/2023

Cyclo therapeutics announces $4.2 million registered direct offering priced at-the-market under nasdaq rules

  • 12/30/2022

Cyclo therapeutics reports third quarter 2022 financial results and highlights recent achievements

  • 11/11/2022

Cyclo therapeutics commences phase 2b study of trappsol® cyclo™ for the treatment of early alzheimer's disease

  • 10/04/2022

Cyclo therapeutics provides business update

  • 09/28/2022

Cyclo therapeutics to present at the h.c. wainwright 24th annual global investment conference

  • 09/07/2022

Cyclo therapeutics provides business update and reports second quarter 2022 financial results

  • 08/16/2022

Cyclo therapeutics to present at the china npc association meeting

  • 08/08/2022

Cyclo therapeutics to present at the nnpdf-inpda conferences 2022

  • 07/21/2022

Cyclo therapeutics to present at the world orphan drug congress usa 2022

  • 07/11/2022

Cyclo therapeutics to present at the 2022 npc patient and family conference hosted by the australian npc disease foundation

  • 06/21/2022

Cyclo therapeutics to participate in the virtual investor alzheimer's disease spotlight event

  • 03/29/2022

Cyclo therapeutics enters research and collaboration agreement with wits commercial enterprise (pty) ltd to explore potential applications of trappsol® cyclo™ to expand pipeline

  • 03/24/2022

Cyclo therapeutics to participate in the 2022 virtual growth conference presented by maxim group llc and hosted by m-vest

  • 03/23/2022

Cyclo therapeutics provides business update and reports full year 2021 financial results

  • 03/14/2022

Cyclo therapeutics to present at the oppenheimer 32nd annual healthcare conference

  • 03/10/2022

Cyclo therapeutics selected to present overview of pivotal phase 3 study for lead candidate, trappsol® cyclo™, at worldsymposium 2022

  • 02/08/2022

Cyclo therapeutics announces formation of global steering committee comprised of leading experts to advise on the global phase 3 clinical development program for trappsol® cyclo™ in niemann-pick disease type c

  • 02/03/2022

Cyclo therapeutics to present at the virtual investor 2022 top picks conference

  • 01/20/2022

Cyclo therapeutics appoints caroline hastings, m.d. as global principal investigator for ongoing transportnpc™ study evaluating trappsol® cyclo™ for the treatment of niemann-pick disease

  • 12/09/2021

Cyclo therapeutics receives ind clearance from the u.s. fda to advance its phase 2 study of trappsol® cyclo™ for the treatment of alzheimer's disease

  • 12/06/2021

Cyclo therapeutics announces pricing of $11.7 million underwritten public offering of common stock

  • 11/16/2021

Cyclo therapeutics announces proposed public offering of common stock

  • 11/16/2021

Cyclo therapeutics provides business update and reports third quarter 2021 financial results

  • 11/15/2021

Cyclo therapeutics to present at the virtual investor roundtable event

  • 11/10/2021

Cyclo therapeutics names preeminent neuroscientist and world-renowned researcher, cynthia a. lemere, phd, as senior advisor for advancement of alzheimer's disease asset

  • 11/02/2021

Cyclo therapeutics recognizes niemann-pick disease awareness month highlighting need for broader awareness and support for research to find a treatment

  • 10/19/2021

Cyclo therapeutics announces abstract accepted for poster presentation at the 14th international congress of inborn errors of metabolism (iciem)

  • 10/18/2021

Cyclo therapeutics to participate in the 2021 virtual cyclodextrin conference hosted by cyclolab

  • 10/06/2021

Cyclo therapeutics appoints lise lund kjems, md, phd as chief medical officer

  • 09/27/2021

Cyclo therapeutics to present at the oppenheimer fall healthcare life sciences and medtech summit

  • 09/15/2021

Cyclo therapeutics to present at h.c. wainwright 23rd annual global investment conference

  • 09/08/2021

Cyclo therapeutics provides business update and reports second quarter 2021 financial results

  • 08/17/2021

Cyclo therapeutics announces new positive safety and efficacy data from ongoing phase 1 open-label extension study of trappsol® cyclo™ for the treatment of niemann-pick disease type c1

  • 07/30/2021

Cyclo therapeutics commences commercial-scale manufacturing for trappsol® cyclo™

  • 07/27/2021

Cyclo therapeutics to present at the 2021 npc patient and family conference hosted by the australian npc disease foundation

  • 06/21/2021

Cyclo therapeutics commences patient enrollment in transportnpc, a pivotal phase 3 study evaluating trappsol® cyclo™ in niemann-pick type c1

  • 06/17/2021

Cyclo therapeutics announces inclusion in the russell 2000® index

  • 06/14/2021

Cyclo therapeutics to present at the jmp securities life sciences conference

  • 06/09/2021

Cyclo therapeutics to participate in the m-vest virtual conference series: alzheimer's disease panel

  • 05/20/2021

Cyclo therapeutics provides business update and reports first quarter 2021 financial results

  • 05/17/2021

Cyclo therapeutics appoints lori mckenna gorski as global head of patient advocacy

  • 05/11/2021

Cyclo therapeutics announces design of pivotal phase 3 study evaluating trappsol® cyclo™ in niemann-pick type c1

  • 04/27/2021

Cyclo therapeutics to proceed with ind filing for phase 2 trial using intravenous trappsol® cyclo™ in alzheimer's disease

  • 04/20/2021

Cyclo therapeutics meets primary efficacy endpoint in phase 1/2 trial from intravenous trappsol® cyclo™ in rare disease niemann-pick type c1 (npc1)

  • 03/25/2021

Cyclo therapeutics provides business update and reports fourth quarter and full year 2020 financial results

  • 03/15/2021

Cyclo therapeutics to participate in inaugural emerging growth virtual conference

  • 03/12/2021

Cyclo therapeutics appoints russ belden as acting chief commercial officer

  • 03/10/2021

Cyclo therapeutics receives positive opinion from the paediatric committee of the european medicines agency on the agreement of a paediatric investigation plan for trappsol® cyclo™

  • 03/09/2021

Cyclo therapeutics announces last patient last visit in phase 1/2 trial evaluating trappsol® cyclo™ for the treatment of niemann-pick disease type c

  • 03/04/2021

Cyclo therapeutics appoints gerald f. cox, md, phd as acting chief medical officer

  • 03/01/2021

Cyclo therapeutics unveils new corporate identity and reaffirms commitment to improving quality of life and providing hope for patients and families

  • 02/22/2021

Cyclo therapeutics presents positive data from clinical development program for lead candidate, trappsol® cyclo™, at worldsymposium 2021

  • 02/09/2021
More Headlines
News

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023. “Our number one priority remains to be the solid operational execution of our TransportNPC™ study. We are very pleased with our continued strong pace o.
  • 11/15/2023

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it had entered into a securities purchase agreement with certain accredited investors (the “Investors”) to raise $2,359,584 in a private offering (the “Offering”). The Investors owned vested warr.
  • 10/23/2023

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Joshua Fine, Chief Financial Officer of Cyclo Therapeutics will present at the 8th Annual Dawson James Conference being held in Jupiter, FL on Thursday,.
  • 10/05/2023

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

  • NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH). Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own. KSF is seeking to determine whether this considera.
  • 09/27/2023

CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders

  • NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Cyclo Therapeutics, Inc. (NASDAQ: CYTH) and Applied Molecular Transport Inc. is fair to Cyclo shareholders. Under the terms of the proposed transaction, Applied Molecular stockholders will receive approximately 0.174 shares of Cyclo for each share of Applied Molecular. Halper Sadeh encourages Cyclo shareholders to click here to learn more about their legal rights and options or conta.
  • 09/21/2023

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

  • GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today that the companies have entered into a definitive agreement (the Merger Agreement) pursuant t.
  • 09/21/2023

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2023. “Over the past quarter, we continued to execute on all fronts. We remain focused on driving recruitment in our pivotal TransportNPC™ study of Trappsol.
  • 08/15/2023

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed the previously announced private placement with Rafael Holdings, Inc. (NYSE:RFL) (“Rafael”) for the purchase of 4,000,000 shares of common stock of Cyclo Therapeutics and warrants t.
  • 08/02/2023

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

  • GAINESVILLE, Fla.--( BUSINESS WIRE )--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 11:00 AM ET.
  • 01/10/2023

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-
  • 09/07/2022

Cyclo Therapeutics to Present at the China NPC Association Meeting

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the 2022 China Nieman Pick Medical Exchange & Sixth Patient Association being held August 13, 2022 in Xiamen,
  • 08/08/2022

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it will participate at the 30th Annual NNPDF Family Support & Medical Conference in conjunction with the INPDA Biennial Meeting being held July 28-31, 2022, in Orlando, FL. “Perspectives from
  • 07/21/2022

Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 in Boston, MA. During the session, Dr. Kjems w
  • 07/11/2022

Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Professor Caroline Hastings, MD will present at the 2022 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 23-24, 2022. Details of the presentation are as f
  • 06/21/2022

Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 PM ET. In addition to the presentation, ma
  • 03/10/2022

Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the poster presentation of its ongoing pivotal Phase 3 study, TransportNPC™ at the 18th Annual WORLDSymposium 2022, a leading medical and scientific conference for professionals working to advance und
  • 02/08/2022

Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 10:00 AM ET. As part of the virtual ev
  • 01/20/2022

Anti-Amyloid Drugs: The Failure Of Success

  • Anti-Amyloid Drugs: The Failure Of Success
  • 01/01/2022

Cyclo Therapeutics (CYTH) Stock: Why The Price Dropped Today

  • The stock price of Cyclo Therapeutics Inc (NASDAQ: CYTH) fell by over 15% pre-market today. This is why it happened.
  • 11/17/2021

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

  • Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease
  • 11/16/2021

Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will participate in the Virtual Investor Roundtable Event on Tuesday, November 16,
  • 11/10/2021

Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today joins with the global Niemann-Pick Disease community in recognizing Niemann-Pick Disease Awareness Month, an initiative to build broader awareness of the impact this disease has on patients, families, and caregivers across the globe. “As a company de
  • 10/19/2021

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstract has been selected for poster presentation at the upcoming 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held November 21-24, 2021 in Sydney, Australia and virtu
  • 10/18/2021

Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it will participate in the 2021 Virtual Cyclodextrin Conference hosted by CycloLab, “Cyclodextrins as active ingredients in the 21st century,” taking place on October 11, 2021. The event will focus on
  • 10/06/2021

Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Lise Lund Kjems, MD, PhD as Chief Medical Officer. Gerald F. Cox, MD, PhD, who has served as the Company's Acting Chief Medical Officer in a consultant role since March 2021, has be
  • 09/27/2021

Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Sharon Hrynkow, PhD, Chief Scientific Officer and Senior Vice President for Medical Affairs of Cyclo Therapeutics, will present at the virtual Oppenheim
  • 09/15/2021

Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. In addition
  • 09/08/2021

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter of 2021, and provided a business update. “Our second quarter was marked by solid execution across multiple fronts. On the heels on positive topline results
  • 08/17/2021

Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced new data from its Phase 1 extension study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (“NPC”), a rare, progressive and fatal genetic disorder characterized by abnorma
  • 07/30/2021

Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has commenced the commercial-scale production of batches of Trappsol® Cyclo™, the Company's proprietary formulation of hydroxypropyl beta cyclodextrin. “Cyclo Therapeutics' robust, scalable an
  • 07/27/2021

Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it will present at the 2021 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 25-26, 2021. The Cyclo Therapeutics session will be held Friday, June 25, 2021, 11
  • 06/21/2021

Cyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol Cyclo

  • Cyclo Therapeutics Inc (NASDAQ: CYTH) has commenced its pivotal Phase 3 study (TransportNPC) evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1). The TransportNPC study has the regulatory and IRB approval required to commence patient enrollment, and site activation is underway.
  • 06/17/2021

Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the commencement of its pivotal Phase 3 study (“TransportNPC”) evaluating Trappsol® Cyclo™, a proprietary formulation of hydroxypropyl beta cyclodextrin, delivered intravenously, for the treatment of
  • 06/17/2021

Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Cyclo Therapeutics has been selected to be added to the Russell 2000® Index effective June 25, 2021, after the close of the U
  • 06/14/2021

Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that N. Scott Fine, Chief Executive Officer, Sharon H. Hrynkow, PhD, Chief Scientific Officer, Senior Vice President for Medical Affairs, and Gerald F. Cox, MD, PhD, Acting Chief Medical Officer of
  • 06/09/2021

CYTH Stock Price: 10.15% Increase Explanation

  • The stock price of Cyclo Therapeutics Inc (NASDAQ: CYTH) increased by 10.15% on Friday May 21. This is why it happened.
  • 05/24/2021

Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer's Disease Panel

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced it will participate in the M-Vest Virtual Conference Series: Alzheimer's Disease Panel on Wednesday, May 26, 2021 at 11:00 AM ET. Cyclo Therapeutics is currently advancing its lead product candidat
  • 05/20/2021

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today reported its financial results for the first quarter of 2021, and provided a business update. “Our team continues to build momentum across multiple fronts and is focused on successfully achieving the multipl
  • 05/17/2021

Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, announced today it has appointed Lori McKenna Gorski as Global Head of Patient Advocacy. “The unmet needs of patients and their families remain at the forefront for Cyclo Therapeutics as we drive the development o
  • 05/11/2021

Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease

  • Alzheimer's disease can largely be stabilized if one inhibits the formation of peroxynitrite, removes it, and partially reverses the damage that it does to the brain through oxidation and nitration. Anavex 2-73, Trappsol Cyclo, and GV-971 probably do all three.
  • 04/28/2021

Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has posted its protocol on www.ClinicalTrials.gov and is preparing to commence its pivotal Phase 3 study evaluating Trappsol® Cyclo™, a proprietary formulation of hydroxypropyl beta cyclode
  • 04/27/2021

Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer's Disease

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (“FDA”) supporting the Company's development strategy to submit an initial new drug application (“IND”) application for a Ph
  • 04/20/2021

7 Beaten Down Stocks with Significant Insider Buying

  • Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.
  • 04/09/2021

CYTH Stock Price Increases Over 10% Pre-Market: Why It Happened

  • The stock price of Cyclo Therapeutics Inc (NASDAQ: CYTH) has increased by over 10% pre-market. This is why it happened.
  • 03/25/2021

Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced topline data from its Phase 1/2 clinical trial, which demonstrated promising safety and efficacy results for Trappsol® Cyclo™ in the treatment of Niemann-Pick Disease type C1, a rare, genetic disea
  • 03/25/2021

Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today reported its financial results for the fourth quarter and full year 2020, and provided a business update. “I am incredibly pleased with the progress we as a company have made over the past year. On the clini
  • 03/15/2021

Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that N. Scott Fine, CEO of Cyclo Therapeutics will present at the Inaugural Emerging Growth Virtual Conference presented by M-Vest LLC and Maxim Group LLC. The conference will take place virtually o
  • 03/12/2021

Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced the appointment of Russ Belden as Acting Chief Commercial Officer. Mr. Belden is a commercialization leader with over 33 years of senior leadership experience in the biotechnology industry, speciali
  • 03/10/2021

Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that the last patient completed their last visit in the Phase 1/2 study evaluating Trappsol® Cyclo™, a proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously (IV) to
  • 03/04/2021

Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021

  • GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer's disease, today announced the presentation of favorable data from its clinical and drug development program for its lead candidate, Trappsol® Cyclo™. These data are being presented at the 17th Annual WORLDSymposium 2021, a leading medical a
  • 02/09/2021

7 Stocks With Insider Buying

  • Insider buying could be a bullish signal for a stock. Why? The insiders may sell for a number of reasons.
  • 02/05/2021

Why Cyclo, Vivos Therapeutics And More Are Moving Today

  • Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Disease Type C. Cyclo Therapeutics is a U.S.-based biotechnology firm engaged in the marketing and sales of cyclodextrins (CD) and related products for food, pharmaceutical, and other industries to be used in diagnostics and specialty drugs with continuing growth in research and new product development.
  • 01/05/2021
Unlock
CYTH Ratings Summary
CYTH Quant Ranking